NCT00592163

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Alaunos Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Conditions

• Advanced Solid Tumors
• Lymphomas

Interventions

Type	Name	Description
DRUG	ZIO-101-C (Darinaparsin)	Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest

Timeline

• Start date: 2007-12-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2008-01-11
• Last updated: 2012-07-19

Locations

1 site across 1 country: Canada